Cell housing device

Patent metadata

Field	Value
Publication number	US-11951206-B2
Application number	US-201816650933-A
Country	US
Kind code	B2
Filing date	Sep 29, 2018
Priority date	Sep 29, 2017
Publication date	Apr 9, 2024
Grant date	Apr 9, 2024

Abstract

The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.

First claim

What is claimed is:

1. A cell housing device, comprising:
a first membrane having a first surface, and a second surface opposing the first surface;
a second membrane opposite and attached to the second surface of the first membrane, wherein the first membrane and the second membrane form an enclosed compartment configured to house a cell population, wherein the enclosed compartment includes a plurality of continuous interconnected compartments formed between the first membrane and the second membrane, and wherein at least one of the first membrane and the second membrane is sintered; and
a frame extending at least partially along an outer edge of the first membrane and the second membrane.

2. The device of claim 1 , wherein at least a portion of the device has a thickness between about 10 μm and about 500 μm.

3. The device of claim 1 , further comprising a plurality of interconnected channels formed between the first membrane and the second membrane.

4. The device of claim 3 , wherein the plurality of channels are arranged in a rectilinear array or a polar array.

5. The device of claim 3 , wherein a center of each of the plurality of channels is separated from the center of an adjacent channel by a distance of about 75 μm to about 2.5 mm.

6. The device of claim 3 , wherein each of the plurality of channels has a height to diameter ratio of at least about 0.2.

7. The device of claim 3 , wherein the device has a number of channels per area along a transverse plane that is greater than about 50/cm 2 .

8. The device of claim 1 , wherein the first membrane and/or the second membrane comprise polyvinylidene fluoride (PVDF), polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE), polycaprolactone (PCL), polyethylene (PE), polyethersulfone (PES), polypropylene (PP), polystyrene (PS), poly(methyl methacrylate) (PMMA), poly(lactic-co-glycolic acid) (PLGA), poly(l-lactic acid) (PLLA), and/or any combination thereof.

9. The device of claim 1 , wherein the frame is configured to receive the first and second membranes.

10. The device of claim 9 , wherein the frame is configured to receive a plurality of first membranes and a plurality of second membranes.

11. The device of claim 1 , wherein the frame comprises a flexing mechanism configured to prevent buckling of the cell housing device.

12. The device of claim 1 , further comprising the cell population.

13. The device of claim 12 , wherein the cell population is capable of glucose-stimulated insulin secretion (GSIS).

14. The device of claim 1 , further comprising a coating on the first membrane and/or the second membrane, wherein the coating comprises a hydrophilic polymer.

15. The device of claim 1 , wherein the device has an insulin diffusion coefficient of about 2×10 −6 cm 2 /s to about 1×10 −5 cm 2 /s.

16. The device of claim 1 , wherein the device has a maximum oxygen diffusion distance of less than about 150 μm.

17. The device of claim 1 , wherein at least one of the first membrane and the second membrane is semi-permeable.

18. The device of claim 1 , wherein at least one of the first membrane and the second membrane is configured to enable vascularization of a cell within the device in absence of an immune suppression therapy.

19. The device of claim 3 , wherein the plurality of channels are generally perpendicular with respect to the first membrane.

20. The device of claim 1 , wherein the compartment has a surface area to volume ratio of at least about 40 cm −1 .

21. The device of claim 8 , wherein the first membrane and/or the second membrane comprise expanded polytetrafluoroethylene (ePTFE).

22. The device of claim 1 , wherein the first membrane and/or the second membrane comprise an average pore size in the range of 5 nm to 2500 nm.

23. The device of claim 1 , wherein the sintered membrane is sintered in a semi-permeable portion of the sintered membrane.

24. A cell housing device, comprising:
a first membrane having a first surface and a second surface opposing the first surface;
a second membrane opposite and attached to the second surface of the first membrane wherein the first membrane and the second membrane form an enclosed compartment configured to house a cell population, wherein the enclosed compartment includes a plurality of continuous interconnected compartments between the first membrane and the second membrane, and wherein at least one of the first membrane and the second membrane is sintered; and
a frame extending at least partially along an outer edge of the first membrane and the second membrane,
wherein a thickness of a portion of the device including the first membrane and the second membrane has a thickness between or equal to 50 μm and 500 μm and wherein a length of the device is between or equal to 4.0 cm and 6.0 cm.

25. The device of claim 1 , wherein both the first membrane and the second membrane are sintered.

26. The device of claim 1 , wherein the first membrane and the second membrane are bonded directly to each other.

27. The device of claim 2 , wherein the portion of the device includes the first membrane and the second membrane.

28. The device of claim 1 , wherein a length of the device is between or equal to 4.0 cm and 6.0 cm.

29. The device of claim 1 , further comprising a plurality of channels formed in at least one selected from the first membrane and the second membrane, wherein the plurality of channels extend at least partially in a thickness direction of the device.

30. The device of claim 29 , further comprising a plurality of through holes formed in at least a portion of the channels, wherein the plurality of through holes extend through the first membrane and the second membrane.

Assignees

• Vertex Pharma

Inventors

• Thanos Christopher
• Lavin Danya M
• Bintz Briannan E
• Bhatnagar Divya
• Mills John
• Billings Megan

Classifications

• A61F2/022

  Artificial gland structures using bioreactors (hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36) · CPC title

• A61K47/32

  Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} · CPC title

• A61K47/34

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

• A61K35/39

  Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36) · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title